ACLX Arcellx, Inc.

BEARISH Impact: 9/10 25-NSE
Horizon immediate Filed Apr 28, 2026 Processed 1mo ago SEC 0001354457-26-000381
Notable filing: 25-NSE
Latest settled — T+1d
ACLX ▲ 0.00% at T+1d
SHORT call ✗ call lost 0.00% · α vs SPY -0.01% · entry $115.07 → $115.07
Next anchor: T+5d due 5w ago
Entry anchored
Apr 27, 03:59 PM ET
via Databento tick
T+1d
0.00%
call 0.00% · α -0.01%
$115.07
settled 6w ago
T+5d
call — · α —
due 5w ago
T+20d
call — · α —
due 14d ago
T+60d
call — · α —
in 6w

Price Chart

Loading chart...

Executive Summary

Arcellx, Inc. (ACLX) has been involuntarily delisted from Nasdaq, with the exchange filing a Form 25-NSE to remove the company's common stock from listing and registration under SEC Rule 12d2-2(a)(3). The delisting is effective immediately as of April 28, 2026, representing a material adverse event that removes the company's primary public trading venue.

Actionable Insight

Traders should expect a catastrophic gap-down at the next available trading opportunity. The stock will likely trade on OTC markets with severely reduced liquidity. Monitor for any subsequent filing regarding a potential appeal or alternative listing venue. Given the $6.7B market cap, this delisting is highly unusual and suggests a fundamental corporate event or regulatory issue not disclosed in this filing.

Key Facts

  • Nasdaq Stock Market LLC filed Form 25-NSE to delist Arcellx, Inc. common stock
  • Delisting effective April 28, 2026 under SEC Rule 12d2-2(a)(3) (involuntary removal)
  • SEC File Number: 001-41259
  • Company had a market cap of $6.7B prior to delisting
  • No prior public disclosure of delisting notice or appeal in provided documents

Financial Impact

Delisting eliminates primary exchange listing for a $6.7B market cap company, likely triggering severe liquidity loss, forced selling by index funds, and potential debt covenant violations

liquiditymarket capitalizationstock pricetrading volume

Risk Factors

  • Complete loss of liquidity as stock moves to OTC markets
  • Forced selling by institutional investors and index funds that require Nasdaq listing
  • Potential debt covenant triggers or credit downgrades
  • Possible underlying corporate event (bankruptcy, fraud, regulatory action) not yet publicly disclosed

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
0% bullish (23 analysts)

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
25-NSE Filing (Primary)0001354457-26-000381
Document: 0001354457-26-000381-index-headers.html0001354457-26-000381
Document: 0001354457-26-000381-index.html0001354457-26-000381
Document: 0001354457-26-000381.txt0001354457-26-000381
3 reports for ACLX
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for ACLX — sortable, filterable
Type Now
Apr 28, 2026
6w ago
25-NSE
BEARISH ★ 9/10
$115.07 $115.07· 0.00%▼ −0.01%
Apr 24, 2026
6w ago
10-K/A
NEUTRAL ★ 2/10
$115.07 $115.07· 0.00%▲ +0.49%
Feb 25, 2026
15w ago
Insider Cluster
BEARISH ★ 7/10
$113.76 $113.88▼ −0.11%▼ −0.65%
Showing 3 of 3

US Market Status

Market Closed — Opens Thu (9h 37m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access